Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
about
Targeting Hsp90 in urothelial carcinomaThe HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damageThe HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update.Synergistic effect of heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin and X-rays, but not carbon-ion beams, on lethality in human oral squamous cell carcinoma cellsMolecular targets for tumor radiosensitization.Therapeutic targeting of receptor tyrosine kinases in lung cancer.Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?Targeting the ubiquitin-proteasome pathway in breast cancer therapy.Novel interaction of the Hsp90 chaperone machine with Ssl2, an essential DNA helicase in Saccharomyces cerevisiae.Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990.Ganetespib radiosensitization for liver cancer therapyOxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivativesHSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.Preclinical evaluation of radiosensitizing activity of Pluronic block copolymersThe heat shock proteins as targets for radiosensitization and chemosensitization in cancerHyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies.Apoptosis and molecular targeting therapy in cancer.The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity.Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity.Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation.Mild hyperthermia plus adenoviral p53 over-expression additively inhibits the viability of human malignant glioma cells.Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature.
P2860
Q27023406-735F3742-25A2-4657-BF7F-1BA2FE9B8B33Q28730558-0A6EB20F-42A9-4A51-A45A-3C45070301CAQ33912171-CD9BA457-D1D6-42A5-8FC9-502096E1E9F9Q35818450-C55086A4-C43B-43EA-BEAC-9E8502AFF3A6Q36066038-E706BAA1-787D-4598-A32E-AA75AC4D33A8Q36086203-B33E4BA8-FFC3-4BE2-91E3-A77550D6E90CQ36126009-EC910C36-7D91-4515-A6DB-1B025E0C56DFQ36158717-93A24F1F-2DA7-4B7E-A73A-54BE2381ED6FQ36187025-92B72823-BFC5-4F1F-BB37-7A45EA202A96Q36429691-5AB65D19-77E4-4E59-A7AA-617058B3D4A2Q36496582-999B7302-C8EA-4851-AE1D-8FC56067A4F5Q36691054-0EFC33C7-0618-4C9C-8221-4F5ADF3370A5Q37013260-8EDA088B-9343-469C-BBD3-696F82AB9817Q37219540-56E113E0-AAF8-45E5-A62E-30794756F465Q37615630-988A85DA-466F-4A7A-B7D5-C3D36A64B59AQ37654601-3C43922C-5B6E-4163-802B-9ECF2188AA21Q37975057-8ABAF6A4-E4AE-4E39-845C-711E2E5A49F1Q38029728-5BDA8F2E-1422-43A1-ADB1-6DB9E030CE83Q38228349-95CEFE00-F47B-4831-993C-8AF64D0E5C29Q38313087-2FF817B7-621A-4195-B48B-96F9D7EE4873Q39203018-78A3781F-CC42-4F64-97EC-C7D4050590E6Q39404697-C4E5700E-39C9-45E1-9F22-BE8C998F7F40Q39700328-F86BBE8A-A13E-4463-A787-3ACE0F694CFAQ40338078-1B8F5FA3-E8A6-425C-9906-5399C13DDC05Q41656985-FAE42D70-38A7-4F24-82AC-1616EA7049D9Q42427997-B7D2D22D-133E-4AF9-976F-0B41DECDA369Q42474860-5A5D5856-3884-47AD-B2DE-C7329E321A36Q45888472-D64D09DB-5F06-4705-85CB-D5026FF4533BQ47770721-C1B75FFE-B3DF-4071-BA5F-74CA0EA23E78
P2860
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
@en
type
label
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
@en
prefLabel
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
@en
P2093
P2860
P1476
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
@en
P2093
P2860
P304
P356
10.1080/09553000310001626135
P577
2003-12-01T00:00:00Z